USD 0.0247
↑ 0.006 (32.09%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ELAB | 32.1 | 18.8 | -73.6 | -92.6 | -96.2 | -99.3 | -99.3 | -99.3 | -99.3 | -99.3 |
| S&P 500 | 0.0 | 0.1 | 2.9 | 10.1 | 14.6 | 35.7 | 27.8 | 93.4 | 193.5 | 33792.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ELAB |
| name | Elevai Labs, Inc. Common Stock |
| price | 0.02 |
| changes percentage | 32.09 |
| change | 0.01 |
| day low | 0.02 |
| day high | 0.03 |
| year high | 4.24 |
| year low | 0.02 |
| market cap | 1219588 |
| price avg 50 | 0.14 |
| price avg 200 | 0.48 |
| exchange | NASDAQ |
| volume | 378026615 |
| avg volume | 61055000 |
| open | 0.02 |
| previous close | 0.02 |
| eps | -0.42 |
| pe | -0.06 |
| earnings announcement | 2024-12-09T05:00:00.000+0000 |
| shares outstanding | 49376038 |
| timestamp | 2024-11-13 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 1712595 | 766277 | 123.50 |
| gross profit | 1134580 | 442275 | 156.53 |
| gross profit ratio | 0.66 | 0.58 | 14.78 |
| research and development expenses | 426243 | 228747 | 86.34 |
| operating expenses | 1134580 | 2230565 | -49.13 |
| interest income | 5564 | 7702 | -27.76 |
| interest expense | 19525 | 2629 | 642.68 |
| ebitda | -3748430 | -1781780 | -110.38 |
| ebitdaratio | -2.19 | -2.33 | 5.87 |
| operating income | -3760081 | -1788290 | -110.26 |
| operating income ratio | -2.2 | -2.33 | 5.92 |
| net income | -4301517 | -1800268 | -138.94 |
| net income ratio | -2.51 | -2.35 | -6.91 |
| eps | -0.4 | -0.19 | -110.53 |
Revenue Growth: revenue decreased to 2 million in 2023 from 1 million in 2022 representing a change of 123.5%. This indicates a sales shrinking, which is a negative sign for the company.
Earnings per Share (EPS): EPS increased to -0.4 in 2023 from -0.4 in 2022 representing a change of -110.53%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Gross Profit: Gross Profit increased to 1 million in 2023 from 0 million in 2022 representing a change of 156.53%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 0 million in 2023 from 0 million in 2022 representing a change of 86.34%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 1 million in 2023 from 2 million in 2022 representing a change of -49.13%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -4 million in 2023 from -2 million in 2022 representing a change of -110.38%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -4 million in 2023 from -2 million in 2022 representing a change of -110.26%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -4 million in 2023 from -2 million in 2022 representing a change of -138.94%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 605529 | 614563 | -1.47 |
| gross profit | 439254 | 425321 | 3.28 |
| gross profit ratio | 0.73 | 0.69 | 4.82 |
| research and development expenses | 52385 | 103194 | -49.24 |
| operating expenses | 1847623 | 2108243 | -12.36 |
| interest income | 64 | 86 | -25.58 |
| interest expense | 30806 | 23537 | 30.88 |
| ebitda | -1383600 | -1352525 | -2.30 |
| ebitdaratio | -2.28 | -2.7 | 15.50 |
| operating income | -1408370 | -1682920 | 16.31 |
| operating income ratio | -2.33 | -2.74 | 15.07 |
| net income | -1412491 | -1397250 | -1.09 |
| net income ratio | -2.33 | -2.27 | -2.60 |
| eps | -0.08 | -0.08 | 4.22 |
Revenue Growth: revenue decreased to 1 million in 2024Q2 from 1 million in 2024Q1 representing a change of -1.47%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Income: Operating income decreased to -1 million in 2024Q2 from -2 million in 2024Q1 representing a change of 16.31%. The decrease in operating income indicates worse operational performance and decreased profitability.
Gross Profit: Gross Profit increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 3.28%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of -49.24%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 2 million in 2024Q2 from 2 million in 2024Q1 representing a change of -12.36%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -1 million in 2024Q2 from -1 million in 2024Q1 representing a change of -2.3%. The increase in EBITDA indicates improved operational efficiency and profitability.
Net Income: Net income increased to -1 million in 2024Q2 from -1 million in 2024Q1 representing a change of -1.09%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 5189918 | 1892183 | 174.28 |
| total liabilities | 1362842 | 760873 | 79.12 |
| total equity | 3827076 | 1131310 | 238.29 |
| cash and cash equivalents | 3326851 | 1154901 | 188.06 |
| short term investments | 0 | 0 | NaN |
| long term investments | 10773 | 10773 | 0.00 |
| total current assets | 4919444 | 1501322 | 227.67 |
| total non current assets | 270473 | 390860 | -30.80 |
| total current liabilities | 1297353 | 588272 | 120.54 |
| total non current liabilities | 65489 | 172601 | -62.06 |
| common stock | 1733 | 957 | 81.09 |
| retained earnings | -7023890 | -2722373 | -158.01 |
| total debt | 210489 | 283217 | -25.68 |
Total Assets: Total Assets increased to 5 million in 2023 from 2 million in 2022 representing a change of 174.28%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 4 million in 2023 from 1 million in 2022 representing a change of 238.29%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 3 million in 2023 from 1 million in 2022 representing a change of 188.06%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 5 million in 2023 from 2 million in 2022 representing a change of 227.67%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 81.09%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 0 million in 2023 from 0 million in 2022 representing a change of -25.68%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 1 million in 2023 from 1 million in 2022 representing a change of 79.12%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 1 million in 2023 from 1 million in 2022 representing a change of 120.54%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -7 million in 2023 from -3 million in 2022 representing a change of -158.01%. This indicates an accumulated losses.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 5080221 | 4226596 | 20.20 |
| total liabilities | 2440585 | 1740250 | 40.24 |
| total equity | 2639636 | 2486346 | 6.17 |
| cash and cash equivalents | 100034 | 943797 | -89.40 |
| short term investments | 0 | 0 | NaN |
| long term investments | 10773 | 10773 | 0.00 |
| total current assets | 2031096 | 3140753 | -35.33 |
| total non current assets | 3049125 | 1085842 | 180.81 |
| total current liabilities | 1935224 | 1222122 | 58.35 |
| total non current liabilities | 505360 | 518128 | -2.46 |
| common stock | 1889 | 1733 | 9.00 |
| retained earnings | -9833631 | -8421140 | -16.77 |
| total debt | 140063 | 175779 | -20.32 |
Total Assets: Total Assets increased to 5 million in 2024Q2 from 4 million in 2024Q1 representing a change of 20.2%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 3 million in 2024Q2 from 2 million in 2024Q1 representing a change of 6.17%. This indicates an increase in shareholders' equity.
Common Stock: Common Stock increased to 0 in 2024Q2 from 0 in 2024Q1 representing a change of 9.0%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of -20.32%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 2 million in 2024Q2 from 2 million in 2024Q1 representing a change of 40.24%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 0 million in 2024Q2 from 1 million in 2024Q1 representing a change of -89.4%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 2 million in 2024Q2 from 3 million in 2024Q1 representing a change of -35.33%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 2 million in 2024Q2 from 1 million in 2024Q1 representing a change of 58.35%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -10 million in 2024Q2 from -8 million in 2024Q1 representing a change of -16.77%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| net change in cash | 2171950 | 743043 | 192.30 |
| operating cash flow | -4556811 | -1585876 | -187.34 |
| free cash flow | -4568002 | -1621403 | -181.73 |
| capital expenditure | -11191 | -35527 | 68.50 |
| depreciation and amortization | 11649 | 6512 | 78.89 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 487738 | 171869 | 183.78 |
| accounts payables | 466891 | 65191 | 616.19 |
| inventory | -265522 | -69328 | -282.99 |
| acquisitions net | 0 | 3500 | -100.00 |
| investments in property plant and equipment | -11191 | -35527 | 68.50 |
| net cash used for investing activites | -11191 | -32027 | 65.06 |
| debt repayment | 0 | 183970 | -100.00 |
| common stock issued | 7463585 | 2178289 | 242.64 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 6738890 | 2362259 | 185.27 |
| cash at end of period | 3326851 | 1154901 | 188.06 |
| accounts receivables | -23218 | -11547 | -101.07 |
| cash at beginning of period | 1154901 | 411858 | 180.41 |
Net Change in Cash: Net Change in Cash increased to 2 million in 2023 from 1 million in 2022 representing a change of 192.3%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2023 from 0 million in 2022 representing a change of -101.07%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -5 million in 2023 from -2 million in 2022 representing a change of -187.34%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -5 million in 2023 from -2 million in 2022 representing a change of -181.73%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from 0 million in 2022 representing a change of 68.5%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2023 from 0 million in 2022 representing a change of 183.78%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 0 million in 2023 from 0 million in 2022 representing a change of 616.19%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| operating cash flow | -780689 | -2324068 | 66.41 |
| free cash flow | -843009 | -2383228 | 64.63 |
| capital expenditure | -62320 | -59160 | -5.34 |
| depreciation and amortization | 24772 | 21188 | 16.92 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | -44855 | 55339 | -181.05 |
| accounts receivables | 25077 | -18119 | 238.40 |
| accounts payables | 350809 | -140698 | 349.33 |
| inventory | -33484 | -449397 | 92.55 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | -59160 | 100.00 |
| net cash used for investing activites | -62320 | -59160 | -5.34 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 0 | 0 | NaN |
| net change in cash | -843763 | -2383054 | 64.59 |
| cash at end of period | 100034 | 943797 | -89.40 |
| cash at beginning of period | 943797 | 3326851 | -71.63 |
Net Change in Cash: Net Change in Cash increased to -1 million in 2024Q2 from -2 million in 2024Q1 representing a change of 64.59%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -1 million in 2024Q2 from -2 million in 2024Q1 representing a change of 66.41%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -1 million in 2024Q2 from -2 million in 2024Q1 representing a change of 64.63%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of -5.34%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of -181.05%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 349.33%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q2 from 0 million in 2024Q1 representing a change of 238.4%. This suggests that the company is less capable of collecting payments from its customers.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.16 | 0.08 | 98.18 |
| net income per share | -0.4 | -0.19 | -111.88 |
| operating cash flow per share | -0.42 | -0.17 | -154.79 |
| free cash flow per share | -0.43 | -0.17 | -149.82 |
| cash per share | 0.31 | 0.12 | 155.44 |
| book value per share | 0.36 | 0.12 | 199.97 |
| tangible book value per share | 0.36 | 0.12 | 199.97 |
| shareholders equity per share | 0.36 | 0.12 | 199.97 |
| interest debt per share | 0.0 | 0.0 | 558.56 |
| market cap | 19665066.54 | 32398134.2 | -39.30 |
| enterprise value | 16548704.54 | 31526450.2 | -47.51 |
| pe ratio | -4.57 | -18.0 | 74.60 |
| price to sales ratio | 11.48 | 42.28 | -72.84 |
| pocfratio | -4.32 | -20.43 | 78.88 |
| pfcf ratio | -4.3 | -19.98 | 78.46 |
| pb ratio | 5.14 | 28.64 | -82.06 |
| ptb ratio | 5.14 | 28.64 | -82.06 |
| ev to sales | 9.66 | 41.14 | -76.51 |
| enterprise value over ebitda | -4.41 | -17.69 | 75.05 |
| ev to operating cash flow | -3.63 | -19.88 | 81.73 |
| ev to free cash flow | -3.62 | -19.44 | 81.37 |
| earnings yield | -0.22 | -0.06 | -293.65 |
| free cash flow yield | -0.23 | -0.05 | -364.15 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | 0.83 | 0.49 | 69.94 |
| current ratio | 3.79 | 2.55 | 48.58 |
| interest coverage | -192.58 | -680.22 | 71.69 |
| income quality | 1.06 | 0.88 | 20.26 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 1.97 | 2.01 | -1.93 |
| research and ddevelopement to revenue | 0.25 | 0.3 | -16.63 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.02 | 89.04 |
| capex to revenue | 0.01 | 0.05 | -85.91 |
| capex to depreciation | 0.96 | 5.46 | -82.39 |
| stock based compensation to revenue | 0.28 | 0.22 | 26.98 |
| graham number | 1.79 | 0.71 | 152.11 |
| roic | -0.98 | -1.58 | 37.85 |
| return on tangible assets | -0.83 | -0.95 | 12.89 |
| graham net net | 0.21 | 0.06 | 277.78 |
| working capital | 3622091 | 913050 | 296.70 |
| tangible asset value | 3827076 | 1131310 | 238.29 |
| net current asset value | 3556602 | 740449 | 380.33 |
| invested capital | 3881792 | 1243138 | 212.26 |
| average receivables | 24507.5 | 7282 | 236.55 |
| average payables | 403493.5 | 154507.5 | 161.15 |
| average inventory | 369707.5 | 217764.5 | 69.77 |
| days sales outstanding | 7.71 | 6.12 | 25.87 |
| days payables outstanding | 376.45 | 237.52 | 58.49 |
| days of inventory on hand | 313.0 | 274.59 | 13.99 |
| receivables turnover | 47.36 | 59.61 | -20.55 |
| payables turnover | 0.97 | 1.54 | -36.91 |
| inventory turnover | 1.17 | 1.33 | -12.27 |
| roe | -1.12 | -1.59 | 29.37 |
| capex per share | 0.0 | 0.0 | -72.07 |
ROE: Return on Equity (ROE) increased to -1.12 on 2023-12-31 from -1.59 on 2022-12-31, representing a change of 29.37%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 3.79 on 2023-12-31 from 2.55 on 2022-12-31, representing a change of 48.58%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -4.57 on 2023-12-31 from -18.00 on 2022-12-31, representing a change of 74.60%. Indicating an increase in the relative valuation of the company's stock.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| ELAB | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.03 | 0.04 | -6.69 |
| net income per share | -0.08 | -0.08 | 4.26 |
| operating cash flow per share | -0.04 | -0.13 | 68.19 |
| free cash flow per share | -0.05 | -0.14 | 66.50 |
| cash per share | 0.01 | 0.05 | -89.96 |
| book value per share | 0.14 | 0.14 | 0.54 |
| tangible book value per share | -0.01 | 0.09 | -111.84 |
| shareholders equity per share | 0.14 | 0.14 | 0.54 |
| interest debt per share | 0.0 | 0.0 | 23.95 |
| market cap | 10785178.34 | 11952235.47 | -9.76 |
| enterprise value | 10825207.34 | 11184217.47 | -3.21 |
| pe ratio | -1.91 | -2.14 | 10.74 |
| price to sales ratio | 17.81 | 19.45 | -8.42 |
| pocfratio | -13.81 | -5.14 | -168.63 |
| pfcf ratio | -12.79 | -5.02 | -155.10 |
| pb ratio | 4.09 | 4.81 | -15.00 |
| ptb ratio | 4.09 | 4.81 | -15.00 |
| ev to sales | 17.88 | 18.2 | -1.77 |
| enterprise value over ebitda | -7.82 | -8.27 | 5.38 |
| ev to operating cash flow | -13.87 | -4.81 | -188.14 |
| ev to free cash flow | -12.84 | -4.69 | -173.63 |
| earnings yield | -0.13 | -0.12 | -12.03 |
| free cash flow yield | -0.08 | -0.2 | 60.80 |
| debt to equity | 0 | 0 | NaN |
| debt to assets | 0 | 0 | NaN |
| net debt to ebitda | -0.03 | 0.57 | -105.09 |
| current ratio | 1.05 | 2.57 | -59.16 |
| interest coverage | -45.72 | -71.5 | 36.06 |
| income quality | 0.55 | 1.66 | -66.77 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 1.66 | 2.37 | -29.70 |
| research and ddevelopement to revenue | 0.09 | 0.17 | -48.48 |
| intangibles to total assets | 0.56 | 0.2 | 180.62 |
| capex to operating cash flow | -0.08 | -0.03 | -213.60 |
| capex to revenue | 0.1 | 0.1 | 6.91 |
| capex to depreciation | 2.52 | 2.79 | -9.90 |
| stock based compensation to revenue | -0.07 | 0.09 | -182.26 |
| graham number | 0.5 | 0.51 | -1.89 |
| roic | -0.53 | -0.68 | 21.17 |
| return on tangible assets | -0.63 | -0.41 | -53.01 |
| graham net net | -0.1 | -0.02 | -511.65 |
| working capital | 95872 | 1918631 | -95.00 |
| tangible asset value | -205430 | 1642841 | -112.50 |
| net current asset value | -409489 | 1400503 | -129.24 |
| invested capital | 3134224 | 2993701 | 4.69 |
| average receivables | 41637.5 | 45183 | -7.85 |
| average payables | 767941.5 | 495698 | 54.92 |
| average inventory | 961806 | 771925.5 | 24.60 |
| days sales outstanding | 4.32 | 7.94 | -45.57 |
| days payables outstanding | 617.39 | 187.97 | 228.45 |
| days of inventory on hand | 529.66 | 449.45 | 17.85 |
| receivables turnover | 20.83 | 11.34 | 83.72 |
| payables turnover | 0.15 | 0.48 | -69.55 |
| inventory turnover | 0.17 | 0.2 | -15.14 |
| roe | -0.54 | -0.56 | 4.78 |
| capex per share | 0.0 | 0.0 | -0.24 |
ROE: Return on Equity (ROE) increased to -0.54 on 2024-06-30 Q2 from -0.56 on 2024-03-31 Q1, representing a change of 4.78%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.91 on 2024-06-30 Q2 from -2.14 on 2024-03-31 Q1, representing a change of 10.74%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.05 on 2024-06-30 Q2 from 2.57 on 2024-03-31 Q1, representing a change of -59.16%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-04 17:45:00
NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company's outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.
Sentiment: Positive
Publish Date: 2024-10-22 09:54:00
NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025 Muscle wasting is a common side effect of popular GLP-1 weight-loss medications, with no current approved treatments.
Sentiment: Positive
Publish Date: 2024-10-21 07:30:00
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
Sentiment: Positive
Publish Date: 2024-10-04 17:08:00
NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an offer to exchange up to 15,000,000 shares of its currently issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) for up to 15,000,000 shares of the Company's newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable in for one share of Series B Preferred Stock.
Sentiment: Negative
Publish Date: 2024-10-03 15:45:00
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Sentiment: Negative
Publish Date: 2024-10-03 07:30:00
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Sentiment: Positive
Publish Date: 2024-10-02 08:30:00
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medic
Sentiment: Positive
Publish Date: 2024-09-24 17:00:00
New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered follow-on offering (the “Offering”) of approximately $8.0 million for its client Elevai Labs Inc. (NASDAQ: ELAB) (the “Company”), a pioneering force in medical aesthetics.
Sentiment: Positive
Publish Date: 2024-09-23 14:35:57
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 50 points on Monday.
Sentiment: Negative
Publish Date: 2024-09-23 08:45:00
NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold.
Sentiment: Positive
Publish Date: 2024-09-10 07:30:00
Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes™ and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months.
Sentiment: Positive
Publish Date: 2024-09-03 07:30:00
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc. Announces Encouraging Research Data Results Indicating Potential for Hair Restoration Using Proprietary
Sentiment: Positive
Publish Date: 2024-08-28 07:30:00
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondria
Sentiment: Positive
Publish Date: 2024-08-26 07:30:00
NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance.
Sentiment: Positive
Publish Date: 2024-08-19 09:00:00
Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai's hUMSC derived exosomes (“ELEVAI exosomes™”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin's extracellular matrix (“ECM”). ELEVAI exosomes™ protein profile detected as part of this study was statistically significant and notably enriched compared to 54 previously published sets of exosome protein data.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
